We are live on ! Find out more
SFCM

Seven Fleet Capital Management Portfolio holdings

AUM $606M
This Fund
S&P 500
This Quarter Est. Return
+32.72%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$606M
AUM Growth
+$288M
Cap. Flow
+$198M
Cap. Flow %
32.7%
Top 10 Hldgs %
65.14%
Holding
138
New
23
Increased
43
Reduced
23
Closed
42

Top Buys

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$118M
2
TNGX icon
Tango Therapeutics
TNGX
+$67.4M
3
RVMD icon
Revolution Medicines
RVMD
+$23.6M
4
PHVS icon
Pharvaris
PHVS
+$18.2M
5
MIRM icon
Mirum Pharmaceuticals
MIRM
+$11.1M

Top Sells

Rank Stock Value
1
TYRA icon
Tyra Biosciences
TYRA
+$7.49M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$4.63M
3
PCVX icon
Vaxcyte
PCVX
+$4.27M
4
SLNO
Soleno Therapeutics
SLNO
+$3.88M
5
KALV
KalVista Pharmaceuticals
KALV
+$2.59M

Sector Composition

Rank Sector Weight
1 Healthcare 99.89%
2 Miscellaneous 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGON icon
1
CG Oncology
CGON
$5.95B
$134M 22.12%
1,886,236
+1,810,478
+2,390% +$118M
TNGX icon
2
Tango Therapeutics
TNGX
$4.2B
$95.7M 15.79%
3,228,144
+2,726,132
+543% +$67.4M
RVMD icon
3
Revolution Medicines
RVMD
$43.9B
$45.3M 7.48%
242,029
+161,237
+200% +$23.6M
PHVS icon
4
Pharvaris
PHVS
$2.25B
$26.8M 4.42%
774,501
+601,770
+348% +$18.2M
LQDA icon
5
Liquidia Corp
LQDA
$6.13B
$20.5M 3.38%
256,603
+68,727
+37% +$3.68M
ELVN icon
6
Enliven Therapeutics
ELVN
$3.28B
$18.5M 3.06%
365,386
+201,356
+123% +$8.55M
ABVX
7
Abivax
ABVX
$7.95B
$14.8M 2.45%
111,334
+68,282
+159% +$7.73M
AVTX icon
8
Avalo Therapeutics
AVTX
$830M
$14.2M 2.35%
770,765
+556,946
+260% +$8.8M
MIRM icon
9
Mirum Pharmaceuticals
MIRM
$5.82B
$12.9M 2.13%
+110,393
New +$11.1M
ASMB icon
10
Assembly Biosciences
ASMB
$482M
$11.9M 1.96%
433,147
+377,000
+671% +$10.3M
IPSC icon
11
Century Therapeutics
IPSC
$302M
$10.7M 1.76%
4,347,826
+1,400,000
+47% +$3.2M
CYTK icon
12
Cytokinetics
CYTK
$8.99B
$10.1M 1.66%
118,240
+56,971
+93% +$4.09M
TSHA icon
13
Taysha Gene Therapies
TSHA
$1.52B
$9.94M 1.64%
1,504,400
+878,692
+140% +$5.2M
MANE
14
Veradermics Inc
MANE
$4.87B
$9.84M 1.62%
+80,000
New +$7.49M
AVBP icon
15
ArriVent BioPharma
AVBP
$1.4B
$8.57M 1.41%
246,606
+196,354
+391% +$5.8M
TARS icon
16
Tarsus Pharmaceuticals
TARS
$3.54B
$7.91M 1.31%
117,067
+97,267
+491% +$6.21M
XNCR icon
17
Xencor
XNCR
$1.77B
$7.83M 1.29%
368,305
+288,305
+360% +$3.6M
ROIV icon
18
Roivant Sciences
ROIV
$25.9B
$7.79M 1.29%
220,126
+91,958
+72% +$2.72M
DMRA
19
Damora Therapeutics
DMRA
$1.28B
$7.4M 1.22%
284,430
+183,182
+181% +$4.44M
AXSM icon
20
Axsome Therapeutics
AXSM
$10.2B
$7.06M 1.16%
28,826
+14,771
+105% +$3.2M
DFTX
21
Definium Therapeutics
DFTX
$4.86B
$6.99M 1.15%
148,647
+48,760
+49% +$1.2M
DNTH icon
22
Dianthus Therapeutics
DNTH
$4.95B
$6.31M 1.04%
64,723
+10,465
+19% +$914K
COGT icon
23
Cogent Biosciences
COGT
$5.61B
$5.71M 0.94%
147,510
-1,889
-1% -$66.1K
ERAS icon
24
Erasca
ERAS
$4.98B
$5.64M 0.93%
308,007
+85,539
+38% +$1.22M
PTGX icon
25
Protagonist Therapeutics
PTGX
$9.18B
$5.57M 0.92%
45,400
+41,400
+1,035% +$4.32M
1
2 3 4 5

Similar funds

NPPM
North Point Portfolio Managers Orange Village, Ohio $606M AUM 20.84% 1-Year Est. Return
SCM
SKBA Capital Management San Francisco, California $606M AUM 13.33% 1-Year Est. Return
BFC
Banc Funds Company Chicago, Illinois $605M AUM 26% 1-Year Est. Return
VV
Verbena Value Westport, Connecticut $605M AUM
CM
Conifer Management New York $607M AUM 29.07% 1-Year Est. Return
RCM
Requisite Capital Management Dallas, Texas $605M AUM 17.2% 1-Year Est. Return
MCM
Mason Capital Management New York $607M AUM 1.77% 1-Year Est. Return
V
VeraBank Henderson, Texas $604M AUM 23.32% 1-Year Est. Return

Seven Fleet Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Seven Fleet Capital Management held 138 positions worth $606M, up 90% from $318M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Seven Fleet Capital Management deployed $198M of net new capital in Q2 2026, opening 23 new positions and adding to 43 existing holdings. Its largest new stake was Mirum Pharmaceuticals: 110,393 shares worth $12.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 56% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Agios Pharmaceuticals, an estimated $4.63M trimmed.

  • Seven Fleet Capital Management's largest Q2 2026 buy was Mirum Pharmaceuticals: 110,393 shares worth $12.9M.
  • Seven Fleet Capital Management added most to CG Oncology in Q2 2026, an estimated $118M increase.
  • Seven Fleet Capital Management's biggest Q2 2026 reduction was Agios Pharmaceuticals, cutting an estimated $4.63M.
  • Seven Fleet Capital Management fully exited Tyra Biosciences in Q2 2026, selling an estimated $7.49M.
  • Seven Fleet Capital Management's ten largest holdings make up 65% of its $606M portfolio in Q2 2026.
  • Seven Fleet Capital Management opened 23 new positions and closed 42 in Q2 2026.
  • Seven Fleet Capital Management's portfolio value rose 90% quarter-over-quarter to $606M.

Based on Seven Fleet Capital Management's 13F filing for Q2 2026, filed 17 Aug 2026.